Beta cells of the pancreas, which make and secrete insulin, do not respond like those of non-diabetic subjects when type 2 diabetes is present. Specifically, subjects suffering from type 2 diabetes have a blunted or even absolute loss of first phase and a severely blunted second phase insulin release in response to glucose. In conjunction with this, and despite all treatments currently available to treat diabetes, beta cell function continues to deteriorate over time. With the data now available from the United Kingdom Prospective Diabetes Study (Sept. 1998) this point was brought home even more forcefully. Despite continual monitoring of patients enrolled in the study, euglycemia could not be maintained even with intensive therapy, because of declining beta cell function. We have been working for some time with GLP-1, a naturally occurring peptide produced and released from the gut in response to food. The amount released depends on the amount of glucose and fat that has been ingested. After its plasma levels increase, GLP-1 binds to the GLP-1 receptor (GLP-1R) on beta cells, and increases PKA activity because of cAMP generation. Downstream of the increased PKA activity, insulin release occurs also in a glucose-dependent manner, plasma glucose having risen because of the meal. The end result is a restoration of plasma glucose back to baseline. Consequently, GLP-1 analogs and GLP-1R agonists are under intense study as treatments for type 2 diabetes. A naturally occurring GLP-1R agonist, exendin-4, is now available for treatment. It binds to GLP-1R with ten times more avidity than does native GLP-1. It contains many amino acids homologous to GLP-1 and, interestingly, contains a unique 9 amino acid C-terminus. We have extensively investigated the functional significance of the C-terminus by studying the effects on GLP-1 when it is added to the C-terminus of GLP-1 and by deleting the 9 amino acids sequentially and in triads from exendin-4. Its addition to GLP-1 improved its binding affinity to its own receptor and its deletion from exendin-4 abrogated its increased affinity for GLP-1R. Another insulinotropic peptide, GIP, is also released from the gut after eating, but, based on BLSA data, beta cells of the pancreas appear resistant to its effects once blood glucose exceed 126 mg/dl. Additionally, in vivo experimental protocols in humans using exogenous GIP have shown that beta cells do not increase insulin secretion in response to exogenous human GIP. GIP is also subject to rapid breakdown by dipeptidyl peptidase 1V. Therefore, we are currently testing in type 2 diabetic humans if a dipeptidyl peptidase 1V-resistant GIP peptide might be successful at increasing insulin secretion from beta cells. This study involves 24 subjects to which increasing concentrations of the peptide have been given up to a maximum of 20 ng/kg/min. This protocol is now finished and the data is being analyzed.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Intramural Research (Z01)
Project #
1Z01AG000905-12
Application #
7732347
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
2008
Total Cost
$444,457
Indirect Cost
Name
National Institute on Aging
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Martin, Bronwen; Golden, Erin; Carlson, Olga D et al. (2009) Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58:318-28
Chia, Chee W; Egan, Josephine M (2009) Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes Metab Syndr Obes 2:37
Chia, Chee W; Carlson, Olga D; Kim, Wook et al. (2009) Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58:1342-9
Kim, Wook; Egan, Josephine M (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60:470-512
Chia, Chee W; Egan, Josephine M (2008) Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 93:3703-16
Elahi, Dariush; Egan, Josephine M; Shannon, Richard P et al. (2008) GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 16:1501-9
Doyle, Maire E; Egan, Josephine M (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113:546-93
Doyle, Maire E; McConville, Patrick; Theodorakis, Michael J et al. (2005) In vivo biological activity of exendin (1-30). Endocrine 27:1-9
Campbell, Vera C; Kopajtic, Theresa A; Newman, Amy Hauck et al. (2005) Assessment of the influence of histaminergic actions on cocaine-like effects of 3alpha-diphenylmethoxytropane analogs. J Pharmacol Exp Ther 315:631-40
Theodorakis, Michael J; Carlson, Olga; Muller, Denis C et al. (2004) Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 27:1692-8

Showing the most recent 10 out of 15 publications